We randomly assigned @ patients with previously untreated CLL and a score higher than @ on the Cumulative Illness Rating Scale ( CIRS ) ( range , @ to @ , with higher scores indicating worse health status ) or an estimated creatinine clearance of @ to @ ml per minute to receive chlorambucil , obinutuzumab plus chlorambucil , or rituximab plus chlorambucil .